EntryPoint Capital’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
JT
CAM
EntryPoint Capital's LGND Position: Q2 2026 in Review
EntryPoint Capital reduced its Ligand Pharmaceuticals (LGND) stake by 56% in Q2 2026, selling an estimated $513K and leaving 1,743 shares worth $551K. The position accounts for 0.13% of the portfolio, ranked #291.
EntryPoint Capital first reported a position in LGND in Q2 2024 and has held it in 5 quarters since. The position peaked at $783K in Q1 2026. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- EntryPoint Capital held 1,743 shares of Ligand Pharmaceuticals worth $551K as of Q2 2026.
- EntryPoint Capital sold 2,179 Ligand Pharmaceuticals shares in Q2 2026, an estimated $513K.
- Ligand Pharmaceuticals made up 0.13% of EntryPoint Capital's portfolio in Q2 2026, its #291 holding.
- EntryPoint Capital first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
- EntryPoint Capital's Ligand Pharmaceuticals position peaked at $783K in Q1 2026.
- 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.